Acne mRNA vaccine for adults with mild facial acne
Official title: A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne
Run by Sanofi · NCT07013747 · Data updated 2026-11-12
This trial will test two injections of an acne mRNA vaccine versus placebo in adults 18–45 with mild facial acne to see if it's safe, triggers an immune response, and improves acne.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 228 (estimated) |
| Sponsor | Sanofi Industry-sponsored |
| Drugs / interventions | chemotherapy, radiation, prednisone |
| Locations | 4 sites (Encino, California and 3 other locations) |
| Status | Recruiting |
| Started | July 3, 2025 |
| Main results expected | June 19, 2029 |
| Study ends | March 13, 2030 |
| Registry record updated | July 9, 2026 |
| Trial ID | NCT07013747 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–45 who are otherwise healthy and have mild facial acne (IGA grade 2) with 10–24 non-inflammatory lesions and 5–19 inflammatory lesions and no nodulocystic disease.
✕Probably not a fit
People with moderate-to-severe or nodulocystic acne, those who are immunocompromised or recently on immunosuppressive therapy, pregnant individuals, or those outside the 18–45 age range are unlikely to benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, placebo-controlled Phase 1/2 trial gives two administrations of a single-dose level acne mRNA vaccine to adults aged 18–45 with mild facial acne, starting with a sentinel cohort followed by a main cohort to monitor safety. Primary outcomes include safety, immunogenicity, and preliminary efficacy compared with placebo, with participants required to meet specific IGA and lesion-count criteria. The Core Study covers initial dosing and follow-up visits, and consenting participants may enter an optional long-term extension for an additional 30 months of follow-up. Study procedures require in-person visits at clinical sites in California and Florida for injections and assessments.
Why it matters
Potential benefit: If successful, the vaccine could reduce acne lesions by inducing a targeted immune response and offer a durable, non-antibiotic treatment option for people with mild acne.
How similar studies have gone: Applying mRNA vaccine technology to acne is a novel approach with limited prior clinical data in acne specifically, although mRNA platforms have been highly successful in other diseases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests as judged by the investigator * Clinical diagnosis of mild facial acne vulgaris with: * IGA score of mild (grade 2 on the 5-grade IGA scale) AND * between 10 to 24 non-inflammatory lesions (ie, open and closed comedones) AND * between 5 to 19 inflammatory lesions (ie, papules and pustules) AND * no nodulocystic lesions (ie, nodules and cysts) Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the first study intervention administration; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * Known systemic hypersensitivity to any of the study intervention components; history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA coronavirus disease 2019 (COVID 19) vaccine * Previous history of or undergoing (suspected or confirmed) myocarditis and/or pericarditis and/or myopericarditis * Skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the study intervention or requires use of interfering topical, systemic, or surgical therapy * Excessive facial hair, facial tattoos, facial skin disorders, skin reactions that may interfere with the study assessments in the investigator's opinion (including - but not limited to - actinic keratosis, eczema, psoriasis, seborrheic dermatitis, rosacea, acute or recent sunburn) or skin infection * Receipt of immune globulins, blood or blood-derived products in the past 3 months * Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Where it's running
-
Encino Research Center- Site Number : 8400008
Encino, California, United States Recruiting -
Moore Clinical Research - Brandon- Site Number : 8400007
Brandon, Florida, United States Recruiting -
Encore Research Group-Jacksonville Center for Clinical Research- Site Number : 8400006
Jacksonville, Florida, United States Recruiting -
DelRicht Research- Site Number : 8400003
New Orleans, Louisiana, United States Recruiting
Study contacts
- Study coordinator: Trial Transparency email recommended (Toll free for US & Canada)
- Email: Contact-US@sanofi.com
- Phone: 800-633-1610
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adapalene/Clindamycin Gel in Vietnamese Acne Patients
This study tests how safe and tolerable and how well Klenzit-C works when used in routine care by Vietnamese patients aged 12 and up with mild to moderate acne.
-
Skincare regimen for mild to moderate acne in people with sensitive skin
A 4-week test will check if a skincare regimen helps with mild to moderate acne in adults with sensitive skin.
-
Engineered Lactobacillus reuteri cream with zinc sulfate–tannic acid MPN coating for acne
This trial will test whether a topical cream containing engineered Lactobacillus reuteri with a zinc sulfate–tannic acid coating can reduce inflammatory acne in adults aged 18–33.
-
Probiotic drink for skin inflammation during the menopausal transition
This study will test whether a daily Lactobacillus casei Shirota probiotic drink can reduce inflammation and improve immune and skin health in women aged 40–60 going through the menopausal transition with inflammatory facial skin conditions.
-
Evaluating the safety and effects of TVB-3567 in healthy individuals and those with acne
This study is testing a new drug called TVB-3567 to see how safe it is and how it works in healthy people and those with acne.
-
Treatment for various skin conditions using AVAVA technology
This study is testing a new device called AVAVA to see if it can help improve skin problems like acne, scars, and wrinkles.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.